Announcements
Projects
Orgs
Project Post
Articles 65
Votes 0
FiercePharma

Authors 4

FiercePharma
Zoey Becker
Kevin Dunleavy
Max Bayer
Pfizer, FDA right the ship at tornado-hit NC production plant - FiercePharma
almost2y
Novartis to buy back $15B in shares despite Entresto setback - FiercePharma
almost2y
Merck applies more pressure against IRA, asking for decision without trial in fight with US government - FiercePharma
~2y
Pfizer, Opko gain FDA nod for weekly growth hormone drug Ngenla - FiercePharma
~2y
GSK and Pfizer RSV shots under CDC scrutiny, with vote today - FiercePharma
~2y
Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's rival PARP med - FiercePharma
~2y
Novo takes action against unlawful sales of Ozempic, Wegovy - FiercePharma
~2y
After metastatic disease win, Merck's Keytruda flunks trial in early stomach cancer - FiercePharma
~2y
Game on, AbbVie. Roche's Columvi nabs FDA nod as 2nd bispecific for large B-cell lymphoma - FiercePharma
~2y
ASCO: Enhertu delivers 'very compelling' pan-tumor activity - FiercePharma
~2y
ASCO: Seagen's top-selling drug under threat as Bristol Myers' Opdivo beats Adcetris in lymphoma - FiercePharma
~2y
PhRMA cries foul on CMS' registry approach for Alzheimer's drugs - FiercePharma
~2y
PhRMA cries foul on CMS' registry approach for Alzheimer's drugs - FiercePharma
~2y
Carrying blockbuster sales expectations, BMS' Camyzos picks up early nod from England's NICE - FiercePharma
~2y
AZ, Merck's Lynparza wins FDA nod in prostate cancer subgroup following advisory committee vote - FiercePharma
~2y
With a tepid recommendation, NICE signs off on Pfizer's Vydura - FiercePharma
~2y
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers - FiercePharma
~2y
FDA clears Braeburn's long-acting Brixadi to treat opioid use disorder - FiercePharma
~2y
Blueprint's Ayvakit picks up long-awaited label expansion - FiercePharma
~2y
SCOTUS hands win to Sanofi, Regeneron in long-running PCSK9 feud with Amgen - FiercePharma
~2y
Takeda braces for impact as Vyvanse edges toward the patent cliff - FiercePharma
~2y
In $1.7B buy, Sobi acquires CTI and myelofibrosis drug Vonjo - FiercePharma
~2y
After production problems, Catalent delays earnings and plans to slash guidance - FiercePharma
~2y
Merck defeats insurers in $1.4B cyberattack appeal - FiercePharma
~2y
Pfizer, Astellas detail Xtandi win in earlier prostate cancer - FiercePharma
~2y